Patient Support

Early launch planning, streamlined patient access, and measured AI adoption help specialty therapy programs accelerate treatment and sustain success.

The PBM’s updated commercial formularies reflect negotiated pricing progress with manufacturers.

As specialty drug launches grow, pharma leaders are rethinking patient access as a core commercialization strategy to reduce delays and improve therapy starts.

Kieran Daly discusses how adherence programs can improve patient outcomes, support specialty pharmacy performance, and reduce healthcare costs.

High copays, restrictive networks, and travel distances leave many rural Americans facing steep barriers to prescription access.

Pharma is moving from centralized patient hub services to a “hubless hub” model, using tech-enabled, distributed access tools to improve speed and outcomes.

As specialty drug costs rise, employers and sponsors must balance alternative funding programs and in-benefit optimization to achieve sustainable savings without disrupting patient care.

As cell and gene therapies move beyond ultra-rare disease indications into broader patient populations, the commercialization infrastructure built around them is due for a fundamental redesign.

CoverMyMeds' Miranda Delatore and Megan Wetzel discuss AI in prior auth and fixing specialty access bottlenecks upstream.

Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years.

Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.

Avalere Health analysts map the converging pressures reshaping the drug pricing and distribution landscape ahead of November.

TailorMed broadens patient support beyond copay help, adding five modules that link access, affordability and adherence across specialty medications.

Fran Gregory, VP of Emerging Therapies at Cardinal Health, discusses key findings from the company's 2026 Advanced Therapy Report.

In a Q&A, Traci Miller discusses the evolving role of hub services as well as their commercial value.

Laura Blair explains why streamlining the patient journey via and simpler tools help ensure adherence from the point of prescription.

Laura Blair discusses what makes enrollment friction, and how the right balance of AI and human support can improve hub utilization and speed to therapy.

Laura Blair discusses how DTP models make manufacturers rethink traditional access and distribution strategies.

Manasi Salgaonkar examines how accurate class of trade research enables precise pricing, contract eligibility, and compliance.

Anthony Bianciella explains how rare disease brands lose patients because journey maps prioritize prescribing intent over the complex, unfamiliar logistics of post-diagnosis access.

Michael Oleksiw says loneliness and behavior gaps drive prescription drop-offs, making early, personalized support critical to adherence.

Traci Miller, senior director of Access and Patient Support at Cardinal Health Sonexus, explains how hub data helps pharma companies shift from reactive firefighting to proactive access optimization.

Pleio CEO Michael Oleksiw discusses how loneliness can affect GLP-1 patient adherence.

Digital tools are improving efficiency, but human engagement remains critical for patient support.

Corey Ford explains why the rise of biosimilars and specialty therapies requires a shift from universal support models to highly tailored strategies.